Lachesis Biosciences
  • Home
  • Our Company
  • Expertise
  • R&D
  • Investors
    • Board
    • News
    • Financials
    • Investor Presentation

News

Picture

Latest News

Jul 2020   Pharmacokinetic bridge study of Rivamist™ nasal spray and Exelon® oral capsule successfully completed.
  • Nasal delivers twice the rivastigmine exposure as oral at an equivalent 3 mg dose
  • Rivastigmine and metabolite (NAP226-90) plasma concentration shown for nasal 4 mg (below left) and oral 3 mg (below right)
Picture
AusIndustry funding support acknowledged.
​
​ACTRN12619001513101, Mean ± SD, n= 16
​
Scientific title: A randomised, crossover, two period, pharmacokinetic, bioavailability and safety study of a single dose of the novel rivastigmine nasal spray and single dose rivastigmine (Exelon, registered trademark) oral capsule in young healthy adult males.

Exelon is a registered trademark of Novartis Corp.

Jun 2020   Australian patent accepted for our nasal drug delivery technology.

Apr 2020   European patent intention to grant notice received for our nasal drug delivery technology.

​Mar 2020   Rivamist trademark filed for our patented Rivastigmine nasal spray.

Dec 2020   Initial usability study of our Rivastigmine nasal spray device successfully completed in AD and PD dementia patients and their carers.

Sep 2019   AusIndustry AC grant received to support the development of our proprietary Rivastigmine nasal spray for AD and PD dementia. 

Aug 2019   United States patent granted for our nasal drug delivery technology.

Journal Publication

  • Morgan TM, Soh B. Absolute Bioavailability and Safety of a Novel Rivastigmine Nasal Spray in Healthy Elderly Individuals. Br J Clin Pharmacol. 2017 83(3):510-516   PMID: 27639640   DOI: 10.1111/bcp.13133​

Conference Posters

  • Morgan TM. Deconvolution of Nasal Absorption of Rivastigmine in Humans and Future Clinical Development. J Prev Alz Dis 2016. 3(4):353; P2-39.
  • Morgan TM. Absolute bioavailability and safety of a novel rivastigmine intranasal spray in healthy elderly individuals. J Prev Alz Dis 2015. 2(4):269-396; P2-55.
Contact
Terms of Use
​Privacy
© COPYRIGHT LACHESIS BIOSCIENCES LTD 2020. ALL RIGHTS RESERVED.
  • Home
  • Our Company
  • Expertise
  • R&D
  • Investors
    • Board
    • News
    • Financials
    • Investor Presentation